20 Things You Didn’t Know About BrainQ
BrainQ is an Israeli startup that provides a platform for healthcare providers to deliver precision neurology therapies in the treatment of brain impairments. The company uses a BCI-based approach in its products and services. The company has made headlines in Jewish business news for its significant impacts in medical industry niches and its recent influx of investor funding. If you’re not familiar with the company and its benefits, here are 20 things you probably didn’t know about BrainQ that you might find intriguing.
1. BrainQ is a young startup
According to Crunchbase, Britain has only been active in business for five years. The company was founded in 2016. The headquarters are located in Jerusalem, Yerushalayim, Israel. The legal name of the business is BRAINQ TECHNOLOGIES LTD.
2. BrainQ is listed across 3 industries
BrainQ is an enterprise that takes a focused approach to the delivery of its products and services. It is listed across three subcategories within the larger health care industry. It is a Health Care company that provides medical practitioners with devices that help them better treat patients with neurological conditions and brain injuries. This has resulted in its listing under health care, medical, and medical devices.
3. BrainQ has three co-founders
BrainQ was founded by Professor Esther Shohami, Yaron Segal, and Yotam Drechsler. This is a first-time entrepreneurial endeavor for all three of the co-founders. Although none have had previous experience launching a new company, each brings a unique set of talents and skills to the group. Through a joint effort and the combining of their skills, knowledge, and professional expertise, they have launched a company that has become quite productive and successful within the medical industry.
4. BrainQ is led by a 6-member core executive team
BrainQ has six members in its core executive leadership team. Yotam Drechsler is the chief executive officer and a co-founder. Yaron Segal is the CINO and co-founder of BrainQ. Professor Esther Shohami is the CSO. Assaf Lifshitz is the vice president of operations. Amit Ashkenazi is the chief technology officer, and Yael Djemal-Kay is the vice president of product and RA.
5. BrainQ has one member on its board of directors
There is one board member listed for BrainQ. Stacey Pugh joined the board of directors on August 16, 2021. She is a recent appointee to the board and currently serves on just one board in an advisory role. She is from the West Coast, the Western part of the United States, based in California. She is a senior vice president and president of Medtronic Neurovascular at Medtronic. Ms. Pugh is uniquely qualified to provide her advisement to the executive leadership staff because of her history and experience in the neurovascular industry and her history of executive leadership experience at a medical facility. She provides advice on strategic planning for the company and helps them with their short-term as well as long-term goal planning.
6. BrainQ operates a simple website
The website for BrainQ is simple yet effective. Visitors enjoy a smooth and seamless experience when visiting the site. The website actively uses 9 technologies to power its features. These technologies are distributed among 10 technology products and services. Some of the technology products and services used include Microsoft Outlook, iPhone Mobile Compatible, Apple Mobile Web Clips Icon, LetsEncrypt, Google Apps for Work, also known as G Suite, HTML5, and a few others. This is far less than most companies require to power their websites. The simplicity of the site means that there is less overhead in IT costs for the services.
7. BrainQ is unique within its industry niche
BrainQ maintains an edge over rivals in the neuroscience and medical devices industries. This is in part by the five registered patents that it has secured with full and sole legal rights to the intellectual property therein. The patents are mostly in the Medical or Veterinary Science Hygiene category. Additionally, the company has also secured two registered trademarks in the medical apparatus and instruments category. Securing sole legal rights to 7 aspects of technology and branding helps BrainQ to maintain uniqueness that makes it stand out from all the other companies offering similar products and services.
8. BrainQ has a low volume of web traffic
We were interested in learning more about the interest that is shown in BrainQs products and services. When we checked out the analytics maintained for web traffic, we learned that the number of monthly visitors that the site receives is low compared to many other large corporate websites. The past 30 days show an average of 2,106 visitors for the month. This gives BrainQ a ranking of number 2,544,795 of the millions of websites registered on the world wide web.
9. BrainQ web traffic comes from two countries
The analytics for the BrainQ website shows that there are two websites maintained for the medical startup. The first is for Israel, with 100 percent of the traffic coming from visitors who live in this region. The second website is from the United States, with 100 percent of the web traffic originating from this country. The number of monthly visits is down for the Israeli site with a 30-day decrease of 0.75 percent, while the website for the United States shows a monthly visits growth increase of 19.2 percent. It appears that for now, at least, interest in the company is higher in the United States.
10. BrainQ is a venture capital-funded enterprise
BrainQ has participated in two rounds of venture capital funding with 1 lead investor and 8 total investors. The total amount raised so far is $48.8 million. The most recent funding round closed on August 16, 2021. This is a significant sum that will help the startup to further grow and develop its operation.
11. BrainQ has high investor confidence
BrainQ has piqued the interest of 8 major investors. Those who provide financial funding for the growth and expansion of its operations include Hnaco Venture Capital, Peregrine Ventures, which is also the lead investor, Dexcel Pharma, OurCrowd, Qure Ventures, IT-Farm, Norma Investment, and Amir Gross. Each of these investors represents groups that have high confidence in BrainQ’s leadership, its products, and the likelihood of success it will achieve in the months and the years to come. The products and services are in demand and the investors know that the odds are good for a healthy return on the investments made. The details of the investment and fundraising agreements have not been shared, but it is assumed that a share in the company’s profits is a part of these agreements.
12. BrainQ offers hope for stroke victims
According to Techcrunch, BrainQ’s device is designed to stimulate damaged parts of the brain from a stroke. This in turn can help to promote the body’s self-repair mechanisms for faster recovery from the damages and symptoms caused by these catastrophic health events. The device is considered to be a breakthrough as studies show that it causes marked improvement. It has received Breakthrough Device certification from the Food and Drug Administration.
13. BrainQ’s device is headed to market
The device that stimulates brain repair is on its way to becoming available commercially. The recent round of fundraising from venture capital investors raised $40 million. These funds are earmarked for use in marketing the new device to medical device providers and health care workers. It can take a lot of funds to market such devices, hence the investor backing to take them into this critical phase in the company.
14. BrainQ went from a concept to reality in five years
In the five years that BrainQ has been working on its medical devices, it took the notion of using technologies to heal the brain to the reality of a device that promotes self-healing. There were many skeptics when the company first set out with its theories and on its mission. Now, the evidence shows that the three co-founders were onto something authentic that is backed by science. Their theories are being proven as realities. The scientific evidence produced through clinical trials shows that this new device could become one of the most effective stroke therapies, bringing relief to those suffering from the aftereffects.
15. BrainQ has a small workforce
According to LinkedIn, BrainQ has accomplished great strides in neurological medicine, but it has done so with a small team of dedicated professionals. The company employs 29 staff members with their various functions. We were interested in finding out if the company was planning to use some of the proceeds of its latest funding round to beef up its current workforce. We discovered that they’re not hiring any more researchers or developers. There is only one position opening for a marketing associate at the headquarters located in Jerusalem, Israel. They’re most concerned with the marketing of their device at this phase of development.
16. BrainQ has a unique staff configuration
Our research into the configuration of the workforce for BrainQ shows that it leans heavily on the business end of things. They employ students, as well as product managers, an innovation officer, human genetics Ph.D. students, a neuroscientist in New Jersey, marketing and business development professionals, an artificial intelligence software engineer, and those attending to executive and business functions. They’ve already developed a revolutionary product. Now it’s time to get it on the market.
17. BrainQ is a privately held company
Currently, BrainQ is a privately owned company that is still under the control of its founders. It’s assumed that the investors are stakeholders in future profits through undisclosed agreements, but the leadership has opted not to file for an IPO at this time. This men’s that you won’t be able to invest shares of BrainQ stock on the public stock exchanges because they don’t exist. It’s unknown at this time if the company will move to the public arena, but for now, investments opportunities are only open to private investors.
18. BrainQ uses advanced technology for healing
According to StartupNation Central, BrainQ is a digital health company that uses the core technologies of artificial intelligence and machine learning to stimulate the brain to repair itself. This in turn helps to repair the interference between the brain and the functions of the body that were affected by an ischemic stroke. For example, a person’s arm may show paralysis. There is nothing wrong with the arm itself, but rather, an interference in signals from the brain that control the function. The device made by BrainQ emits waves that stimulate certain affected parts of the brain to make self-repairs, which restore normal functioning of affected body parts. As a society, we’ve been looking toward new technologies to uncover their true potential for helping mankind within the medical industry. BrainQ has uncovered one of these secrets in a device that could forever change our world and improve the overall quality of life.
19. BrainQ may be a game-changer
There is a strong likelihood that the device BrainQ plans to market shortly will not only help stroke victims but also other people with brain impairment. It makes sense that if it can cause the brain to repair damaged segments, the technology may one day be improved to impact other neurological conditions. The implications for future use are immense.
20. BrainQ is a company to keep your eye on
Although BrainQ is still a relatively small company, it has expanded into the United States from Israel. Whether you’re a medical practitioner, stroke victim, investor, or simply an interested party, this is a startup that bears watching. This company has provided a useful device for improving the quality of life for stroke victims. It’s hoped that their research and development will continue to other aspects of health and life sciences. This is an amazing discovery with far-reaching implications for improving the quality of life for some. With the evolution in technology and new advancements, who knows what will be possible in a few short years. We’re placing our bets on BrainQ to continue its research and provide yet more devices for improved health for others suffering from brain-related conditions.
